Cara Therapeutics, Inc. (NASDAQ:CARA) announced its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.03), Briefing.com reports. During the same period last year, the firm posted ($0.42) EPS.
Cara Therapeutics (NASDAQ:CARA) traded down $0.67 during trading hours on Friday, reaching $11.51. 438,755 shares of the company were exchanged, compared to its average volume of 835,692.
CARA has been the topic of a number of research reports. Scotiabank boosted their target price on shares of Cara Therapeutics from $31.00 to $31.50 and gave the stock an “outperform” rating in a report on Tuesday, October 17th. Zacks Investment Research downgraded shares of Cara Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, October 4th. Needham & Company LLC restated a “buy” rating and issued a $23.00 target price on shares of Cara Therapeutics in a report on Wednesday, October 4th. ValuEngine downgraded shares of Cara Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, September 27th. Finally, Piper Jaffray Companies set a $27.00 price target on shares of Cara Therapeutics and gave the company a “buy” rating in a report on Saturday, August 5th. One research analyst has rated the stock with a sell rating, four have given a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company. Cara Therapeutics presently has an average rating of “Buy” and a consensus price target of $25.46.
ILLEGAL ACTIVITY WARNING: “Cara Therapeutics, Inc. (CARA) Announces Quarterly Earnings Results” was published by Community Financial News and is owned by of Community Financial News. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this piece of content can be accessed at https://www.com-unik.info/2017/11/03/cara-therapeutics-inc-cara-announces-quarterly-earnings-results.html.
Cara Therapeutics Company Profile
Cara Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. It is developing a class of product candidates that target the body’s peripheral nervous system.
What are top analysts saying about Cara Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Cara Therapeutics Inc. and related companies.